Home › Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients
 

Keywords :   


Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

2015-02-09 15:30:43| Biotech - Topix.net

Oncolytics Biotech Inc. today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN for the treatment of high grade gliomas in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN can infect a variety of brain tumors when delivered intravenously.

Tags: high drug grade patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »